FlexTrade Integrates Glimpse Markets Data to Optimise Price Discovery in Fixed-Income Trading
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems and Glimpse Markets, a buy-side data sharing platform for bond markets, announced the full integration of Glimpse trading data into FlexTrade’s Fixed Income EMS solution: FlexFI.
Glimpse Markets is a buy-side driven data sharing network that provides contributors access to unfiltered post-trade bond execution data. It unlocks previously inaccessible trade information transforming how traders and portfolio managers source liquidity, price bonds, and ensure best execution.
With this two-way integration, fixed-income traders can seamlessly incorporate and process vast volumes of Glimpse’s raw aggregated trade data and incorporate it into FlexFI’s Bond Widget. Using FlexFI’s sophisticated visualisation tools, data can be displayed and understood in an easy-to-consume format. Further dynamic sorting can be applied to quickly search and analyse different bonds from the Glimpse data set. When viewed alongside other market data sources and liquidity, it can enhance price discovery and deliver a consolidated view of the market for fixed-income trading.
Additionally, using FlexFI’s robust and flexible APIs, fixed-income teams can contribute back to Glimpse’s network of pooled buy-side data by uploading their end-of-day files in multiple formats, minimising effort and operational overhead.
Paul O’Brien, Founder and Chief Executive of Glimpse Markets, stated:“Integrating with leading EMS vendors is a crucial priority for Glimpse to ensure the breadth of data we offer is being incorporated into our clients’ fixed income trading workflows as seamlessly as possible. It’s exciting to see the new, innovative ways EMS vendors such as FlexTrade are taking this to the next level and unlocking unique insights from the Glimpse dataset, which will ultimately be beneficial to the end investor.”
Andy Mahoney, Managing Director, EMEA at FlexTrade, noted: “The incorporation of Glimpse’s innovative data offering into our fixed-income EMS, FlexFI, has the power to transform how the analytics are used. As a first step, taking the raw data and displaying it in a visually rich format can help provide actionable insights to optimise price discovery. Looking further ahead, this integration also presents multiple opportunities for how fixed-income traders could leverage the trading data. For example, traders could tap Glimpse data as an input to AI-driven automation workflow strategies in the future.”
About FlexTrade Systems:
FlexTrade Systems is a global leader in high-performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognised for introducing FlexTRADER®, the world’s first broker-neutral, execution management trading system, which allows clients to completely control and customise their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.
About Glimpse
Glimpse is a buy-side data sharing network focused initially on the corporate bond market as well as emerging markets. Participating clients send agreed subsets of their trading data to Glimpse who then aggregate, anonymise, and re-distribute the data to all members of the network. Glimpse’s offering is underpinned by a “Give to Get” model whereby clients must contribute their trading data to receive the aggregated, anonymised data from all other members. There is no cost to participate, and all clients can monetise the data they contribute via a pro-rata profit sharing agreement. The initiative is driven and shaped by its buy-side Advisory Board.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005320/en/
Contact information
Iain Smith
Iain.Smith@flextrade.com
o: +44 20 3757 9311 x 9311
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom